ARG1 and cancer: It can therefore be concluded that OATD-02, as the dual arginase inhibitor, may improve anti-cancer therapy, which seems to be linked to the inhibition of cellular arginases, ARG2-dependent metabolic adaptations, and ARG1 located in EVs.